Prognosis and prognostic factors of lung cancer complications in patients with rheumatoid arthritis

Int J Rheum Dis. 2024 Mar;27(3):e15069. doi: 10.1111/1756-185X.15069.

Abstract

Aim: To clarify the prognosis and prognostic factors for lung cancer in patients with rheumatoid arthritis (RA).

Methods: In this retrospective longitudinal study, we investigated the medical records of patients with RA among 1422 patients diagnosed with lung cancer and registered in a hospital-based cancer registry between January 2013 and May 2022. The Kaplan-Meier method and Cox proportional hazards model were used to analyze survival and identify predictive factors.

Results: Of 26 patients with RA complicated with lung cancer (median age, 69 years), the 2-year overall survival rates for stages I-II were 90%-100%, and those for stages III-IV were 20%, respectively. Positivity of anti-citrullinated protein/peptide antibody, smoking history, interstitial lung disease, poorly controlled RA, stage III and IV lung cancer, histological types other than adenocarcinoma and squamous cell carcinoma, and RF ≧ 50 IU/mL were associated with increased mortality. After the surgical resection of stage I and II lung cancer, 5 of the 16 patients experienced cancer recurrence after resumption of RA treatment, and the histology of the recurrent cancers was mostly squamous cell carcinoma.

Conclusions: Early detection of lung cancer is needed, especially in patients with RA who have a history of smoking, seropositivity, or interstitial lung disease. Even after surgical resection, it should be noted that squamous cell carcinoma is prone to recurrence.

Keywords: lung cancer; prognosis; relapse; rheumatoid arthritis; squamous cell carcinoma.

MeSH terms

  • Aged
  • Anti-Citrullinated Protein Antibodies
  • Arthritis, Rheumatoid* / complications
  • Arthritis, Rheumatoid* / diagnosis
  • Arthritis, Rheumatoid* / epidemiology
  • Carcinoma, Squamous Cell* / diagnosis
  • Carcinoma, Squamous Cell* / epidemiology
  • Carcinoma, Squamous Cell* / therapy
  • Humans
  • Longitudinal Studies
  • Lung Diseases, Interstitial* / diagnosis
  • Lung Diseases, Interstitial* / epidemiology
  • Lung Diseases, Interstitial* / etiology
  • Lung Neoplasms* / complications
  • Lung Neoplasms* / diagnosis
  • Lung Neoplasms* / epidemiology
  • Neoplasm Recurrence, Local / complications
  • Prognosis
  • Retrospective Studies

Substances

  • Anti-Citrullinated Protein Antibodies

Grants and funding